(Voting Panel Chairman)
Throughout his career, Ian has been involved in the quoted growth companies sector. His early career was as a stockbroker, analyst, broadcaster and financial journalist in this area and, since founding The Design Portfolio Marketing Services in 1991, he has been active in helping many companies in this sector with their investor communication and corporate reporting requirements. Ian is also Chairman of Flathill Communications Group plc, President of The Design Portfolio Marketing Services Inc. and a member of the Investor Relations Society.
Renee is a Managing Partner of Positive Capital Partners and was previously a Partner and COO of Omega Funds. Prior to Omega, she served as a Partner in the Venture Capital group 3i Group plc in London where, since 2005, she was responsible for managing their publicly quoted assets and European legacy healthcare portfolio. In addition, whilst at 3i, Renee structured and executed several secondary sale processes. Prior to this she was a European Group Head and MD in Investment Banking and has over 12 years of corporate finance experience with firms such as BT Alex Brown, Deutsche Bank and Lehman Brothers, where she focused on raising M&A and private and public capital for growth companies in both Europe and the US. Prior to Investment Banking, Renee worked for five years in European sales and marketing for a financial services-focused software business. Renee has a BA in Finance from Stockholm School of Economics and a MBA from INSEAD. She has significant Board experience from both private and public Board work and is presently a Board member of Scibase AB, Simparel Inc and EnXray Limited.
Amit is Senior Scientific Analyst at Sphera Global Healthcare Fund. His earlier experience includes two years as Business Development and Pipeline Manager at ATI Technological Incubator, and four years in marketing, sales and business development in medical devices companies, mainly in global markets. Amit holds an MD from the Technion – Israel Institute of Technology, Haifa.
Chris has more than 15 years of experience in strategic communications across the Healthcare sector and has worked with companies at all stages of development, including for some of the world’s leading pharmaceutical and biotechnology companies. He has led communications strategies on multiple cross‑border IPOs, private fundraisings and international M&A. His corporate communication experience includes extensive profile‑raising campaigns to support companies’ business objectives and crisis communication.
Chris was formerly a Director in the Life Sciences team at Citigate Dewe Rogerson, where he worked from 2003 to 2015, and an Associate Director at former specialist bioscience communications consultancy, HCC De Facto. He has degrees in Biological Sciences and Psychology, a background in journalism and a PhD in Molecular Biology.
Stefan is a Director, Equity Research in the No.1 Extel (2015) ranked Healthcare & Life Sciences team at Numis Securities, where he covers a variety of UK-listed firms across the sector. Stefan joined Numis from Peel Hunt where he helped the team achieve a No.1 Extel ranking in the sector for three years in a row (2012–14) and raise over £1bn for mid and small-cap healthcare and life sciences companies. Prior to that, Stefan was a founder of independent research house Clear Capital, where he built a leading life sciences franchise through several acquisitions from 2003–10, following several years in strategy consulting. Stefan has a PhD in Antibody Engineering from the University of Cambridge and is a CFA Charterholder.
Carl Harald was appointed as Investment Manager to SV Life Sciences Managers LLP in 2013 where his team runs the quoted side of their portfolio. SVLSM acts as Alternative Investment Fund Manager for International Biotechnology Trust Plc, where Carl Harald is also a member of the Investment Committee.
Carl Harald qualified as a medical doctor in 1981, completed his PhD in 1990 at the Karolinska Institutet and qualified as a Certified European Financial Analyst from the Stockholm School of Economics in 1999. In 1992, he joined Astra Arcus and, in 1997, he began to combine his medical and pharmaceutical industry insights with finance by working as a Senior Financial Analyst for Hagströmer & Qviberg and then Danske Securities.
In 2000 he gained a role as Senior Portfolio Manager at Carnegie Investment Bank in Stockholm, where he managed various funds. A key highlight during this period was the outstanding performance of the Carnegie Biotechnology Fund for which, as Principal Fund Manager, Carl Harald was recognised by Bloomberg as the top performing biotech fund manager worldwide.
Erik became Executive Director, Life Sciences & Healthcare at Kempen & Co Corporate Finance in 2012. His previous roles include Friesland Bank (District Manager Alkmaar); Crucell (Director of Business Development and Operations); Rabo Securities (Senior Equity Analyst); and Sanquin (Post-doctoral Researcher). Erik has a PhD in Molecular Microbiology and an MSc in Medical Biology.
Joep joined LSP in 2007 and became a Partner of the firm in that same year. Joep’s prime focus and responsibility within LSP is to invest in listed securities. Prior to joining LSP, he held the position of Director Corporate Finance and Capital Markets at Fortis Investment Banking (now part of ABN AMRO) where he played a key role in the origination and execution of numerous financial and strategic transactions for healthcare companies, both in Europe and the US. He has also gained business development and technological transfer experience in a commercial setting. Awarded a PhD in Molecular Biology by the prestigious European research institute EMBL in Heidelberg, Germany, Joep has a strong scientific background. In addition, Joep holds a Master’s degree in Biochemistry from the University of Nijmegen, the Netherlands.
Tara has a BSc in Biochemistry and a PhD in Structural Biology, both from Imperial College London. She worked with the top-ranked European Healthcare Equity Research team at Lehman Brothers/Nomura. She then moved to Jefferies, where she spent several years as part of the European Biotechnology and Life Sciences Equity Research team. Prior to her role as the Healthcare Analyst at Shore Capital, Tara set up her own life sciences consultancy.
Julie joined Panmure Gordon in November 2015 from Canaccord Genuity. She has 18 years’ experience in Life Sciences research, covering both UK and continental European companies across a wide range of Healthcare subsectors. These include biotechnology, medical devices, diagnostics and healthcare services across both large and small-cap companies. Prior to Canaccord Genuity Julie was a member of the No.1 Extel‑rated healthcare team at Piper Jaffray. Julie started her City career at Beeson Gregory, where she became Head of Lifesciences research. Julie has a PhD in Microbiology from the University of Kent and experience in industry in both Europe and the US. She is also panel member for NIHR i4i (invention for innovation), assessing early stage medical technologies.
James has over 18 years of experience of advising UK growth companies with over 10 years dedicated to healthcare. He has overall responsibility for all corporate relationships within Peel Hunt’s healthcare franchise. Prior to joining Peel Hunt in 2009, James was a senior banker in Piper Jaffray’s European healthcare IB team with a focus on ECM and M&A mandates.
Gary is an experienced healthcare analyst having worked in the City since early 2001. He joined Zeus Capital in January 2014 and is responsible for research coverage of Life Sciences, including companies active in biotechnology, specialty pharmaceuticals, medical technology and clinical research services. He has worked on numerous IPOs and M&A mandates in the UK and Europe and has previously worked at Nomura Code Securities and KBC Peel Hunt. Prior to becoming an analyst, he managed an R&D group at a Canadian biotech company and before that he was a post‑doctoral Fellow at the Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland. His academic training includes an MBA from the University of Durham Business School and a PhD in Immunology from the Faculty of Medicine at Monash University (Melbourne, Australia) where he also obtained a BSc.
Mette is Managing Partner in Lundbeckfond Ventures, an evergreen life science venture fund. Mette has more than 20 years of broad international experience within biotech and life science, covering business development and licensing, management, and financing. She was previously co-founder and CEO of 7TM Pharma. Prior to that she was part of the management team of NeuroSearch A/S responsible for business development and licensing and has, over the years, co-founded several biotech companies. She started her career as a Patent Agent. Mette has been appointed to numerous Board positions both in private and public companies. Mette graduated with a degree in Biology from the University of Copenhagen and also has an MBA.
Victoria joined JP Morgan Asset Management in the European Research team covering the Healthcare sector nine years ago, after starting in the investment bank in 2004. She also contributes to the JP Morgan Global Healthcare Fund. Victoria achieved a top five ranking in the 2015 Extel buyside survey in both the Pharma & Biotech and Medtech sectors. She became a CFA Charterholder in 2009 and has a BSc in Chemistry from Durham University.
Albert is the Head of International Listings at Euronext, the most liquid single order book stock exchange in Europe, with listings venues in London, Paris, Amsterdam, Brussels and Lisbon. From 2011–2013, Albert led the EMEA International Listings team of NYSE Euronext and oversaw over 25 IPOs of EMEA‑based companies on the New York Stock Exchange. Prior to this Albert was an investment banker with Deutsche Bank, Carlton Partners and Religare Capital Markets. Albert has an MBA from London Business School.
Eva is Senior Consultant, responsible for Investor Relations and Public Relations in Hume Brophy’s varied International Healthcare Practice serving companies large and small. She has 20 years of experience in fund management and equity analysis of companies across the global Healthcare sector. Most recently she was at Schroder Investment Management for 13 years, of which seven were spent in New York, where she was responsible for the analysis and valuation of publicly listed and about-to-be-listed healthcare companies in the US. Eva has a PhD from the University of Bristol. She is also a fluent German speaker.
Anne Hennecke joined MC Services in 2011. Prior to this, she held senior management positions in international pharma and biotech companies. Most recently she headed the Investor Relations and Corporate Communications department of Evotec AG for 10 years and was a member of the Company’s Executive Committee. Previously, she was responsible for Investor Relations and Corporate Communications at Schwarz Pharma AG, where she initially held management positions in the International Marketing Department.
Anne has 20 years’ experience in Financial and Strategic Communications. During her career she managed Evotec’s IPO on the Frankfurt Stock Exchange and Nasdaq, multiple M&A programmes, and major financial transactions. Anne is a pharmacist and marketing expert by training.
Tony is Director of Business Development at One Nucleus. After completing a PhD in Biochemistry at the University of Southampton in 1992, Tony undertook several years of post-doctoral research in the oncology field, primarily with the Imperial Cancer Research Fund (now CRUK). In 1997, he moved into Technology Transfer with the Medical Research Council and later (1998) University College London, at the Wolfson Institute for Biomedical Research.
In November 2003, Tony took up the post of Director of Biotechnology & Healthcare at London First, managing the London Biotechnology Network and promotion of London’s excellence in healthcare research and delivery. In May 2010 he took the London Biotechnology Network into the merger with ERBI, seeing this as the best manner in which to continue assisting member companies develop their businesses.
His role at One Nucleus encompasses the development of the membership offer to reflect the current external environment and changing needs placed upon members’ businesses. He leads on delivery of the BioWednesday events series and the annual Genesis Conference.
Howard joined Canaccord Genuity in January 2016. From 2000 to 2007, Howard was a Life Science Analyst at Teather & Greenwood/Landsbanki, becoming Head of Research in 2004. During this period, Howard provided equity research on UK listed large and small-cap pharmaceutical, biotech, diagnostic and medical device businesses, and was lead analyst on multiple IPOs and ECM transactions. In 2007, Howard joined Oakes, Lyman & Co. Limited, working with their portfolio of private medical device companies on financing and strategy. He was appointed CFO and Executive Director of orthopaedic regenerative medicine businesses CellCoTec Limited (in 2010) and Orteq Limited (in 2014), and managed the operational merger of the two businesses, as well as multiple financings.
David Pinniger is a Fund Manager with the Polar Capital Healthcare team, and has over 14 years of investment experience in healthcare, specialising in biotechnology. He has managed investments across both venture and specialist funds for firms including SV Life Sciences, Abingworth and Morgan Stanley. David holds a first class honours degree in Human Sciences from the University of Oxford, and is a CFA Charterholder.
Nick is an experienced non-executive director and chairman with a background as a successful corporate financier. He has considerable experience of businesses in the healthcare, medical, biotechnology environmental and technology industries.
Until February 2016, Nick was Chairman of Oxford BioMedica plc, a leading gene-based biopharmaceutical company. Nick is also chairman of SEHTA, one of the largest health technology networking organisations in the UK. Until March 2013 Nick was the Chief Executive of Ipso Ventures plc, a creator and investor in early stage technology and healthcare businesses. As such he created eight businesses around university technology.
Sachin Soni is the promoter, co-founder and portfolio manager of Third Eye Fund. Prior to incorporating Third Eye in 2016, Sachin worked as an Equity Research Analyst on the Life Sciences team in the Securities division of Kempen & Co, and became a Director and Head of the Life Sciences team. During his eight years at Kempen & Co from 2008 to 2016, he led a team of five, was responsible for coverage of the European Life Sciences and Healthcare sector and won Extel and StarMine awards for stock picking. He has over ten years of experience in Life Sciences, with an exposure to both private (Venture Capital) and public market investments, and has been involved in multiple IPOs and secondary transactions, raising over €1.0bn for various life sciences companies.
Melanie is a Partner, Life Sciences at Instinctif Partners and she leads on financial communications within the life sciences team. She has 20 years of experience advising life sciences companies on financial communications. Prior to joining Instinctif Partners, she built and established the life sciences practice at the Hogarth Partnership. She was a Partner in the Financial Dynamics (now FTI) Life Sciences team and a Director at Merlin Financial PR. She has extensive experience of capital market transactions and corporate issues facing the pharma, biotech, medtech and healthcare industries, as well as advising specialist VCs and IP commercialisation companies. Before entering business communications, she was at Price Waterhouse where she qualified as a Chartered Accountant. She has a BA in Biochemistry from the University of Oxford.
As a Principal and Analyst on the Private Transactions team, Elise provides extensive research and analysis on individual companies operating in the healthcare industry in both the US and Europe. Prior to joining Deerfield in 2010, Elise began her career in healthcare in 1987 as a Venture Capitalist and Banker at PaineWebber Inc. and was an officer of PaineWebber Development Corporation, which managed nearly $1.0bn in assets representing three PaineWebber funds and several research and development limited partnerships invested in biotechnology and high technology companies. From 1996 to 2007, Elise was a Senior Research Analyst and Managing Director in healthcare, primarily covering the biotechnology industry at PaineWebber Inc. (1996–2001) and Citigroup (2001–2007). She holds an AB in Engineering Sciences with a specialty in Biomechanics from Harvard University and an MBA from Harvard Business School.